Pharma and life sciences: where cybersecurity meets validated systems

In a validated environment, a security patch is a change to a system whose correct operation has been formally demonstrated. That single fact explains most of what makes life sciences security distinctive - and most of the friction between security teams and quality teams.

What validation changes

Systems affecting product quality, patient safety or regulatory decisions are validated: documented evidence that they perform as intended. Any change risks the validated state, so changes go through formal control with assessment, testing and approval.

Consequences security teams find frustrating and quality teams consider non-negotiable:

• Patching is not routine - it is a change requiring impact assessment and often revalidation testing.
• Emergency patching needs a defined, pre-agreed path or it stalls at the moment it matters most.
• Some systems run unsupported software because revalidating on a new platform is expensive.
• Configuration changes, including security hardening, are changes.

The workable answer is the same as in operational technology: where you cannot patch promptly, compensate - segmentation, monitoring, strict access - and document it as an accepted risk with a named owner. Pretending the patching SLA is met is what fails an inspection.

Data integrity is the regulator's focus

Inspectors care intensely about whether records can be trusted. The ALCOA principles - attributable, legible, contemporaneous, original, accurate, and commonly extended with complete, consistent, enduring and available - drive specific technical expectations:

• Audit trails that record who did what and when, and that users cannot disable or alter.
• Unique user accounts. Shared logins break attributability and are a classic inspection finding.
• Time synchronisation, because contemporaneous means the timestamp must be trustworthy.
• Controlled deletion - records amended by appending, never overwritten.
• Backup and archive that keeps records retrievable for long retention periods, including the ability to read old formats.

Notice how closely these align with ordinary security controls. Access management, logging and integrity protection satisfy both agendas - which is the basis for running one control set rather than two programmes.

The wider obligation set

• Clinical trial data - special category personal data at scale, with consent, transfer and retention obligations.
• Manufacturing OT - production systems with the same availability and safety constraints as any industrial environment.
• Intellectual property - research data is a primary target for state-aligned actors, and the exposure is strategic rather than operational.
• Supply chain - contract manufacturers and research organisations handling your regulated data.
• Serialisation and track-and-trace systems, which are both regulated and internet-connected.

Making the two functions work together

The recurring failure is security and quality operating separately, producing duplicated controls and contradictory instructions. What works: joint change assessment so security impact and validation impact are considered together, a pre-agreed emergency security change path, shared evidence, and security involvement at system selection rather than after validation.

Key takeaways

• Validation makes patching a change, not a routine - agree an emergency path.
• Data integrity expectations align closely with ordinary security controls.
• Shared accounts break attributability and are a classic finding.
• Joint change assessment prevents duplicated and contradictory controls.